CN103404707A - Application of bacteroides fragilis in preparation of compositions for preventing intestinal diseases of animals - Google Patents
Application of bacteroides fragilis in preparation of compositions for preventing intestinal diseases of animals Download PDFInfo
- Publication number
- CN103404707A CN103404707A CN2013103599509A CN201310359950A CN103404707A CN 103404707 A CN103404707 A CN 103404707A CN 2013103599509 A CN2013103599509 A CN 2013103599509A CN 201310359950 A CN201310359950 A CN 201310359950A CN 103404707 A CN103404707 A CN 103404707A
- Authority
- CN
- China
- Prior art keywords
- bacteroides fragilis
- application
- composition
- preparation
- animals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Fodder In General (AREA)
Abstract
The invention relates to the technical field of application of bacteroides fragilis, and in particular relates to an application of bacteroides fragilis in preparation of compositions for preventing intestinal diseases of animals. The invention explores a novel use of bacteroides fragilis and opens up a novel application field. Experiments show that bacteroides fragilis as a kind of probiotics can be used for preparing animal feed additives to prevent intestinal diseases of animals so as to promote healthy growth of animals.
Description
Technical field
The present invention relates to the applied technical field of bacteroides fragilis, be specifically related to the application of bacteroides fragilis in the composition of preparation prevention animal intestinal disease.
Background technology
Probio is the active microorganism that a class is useful to the host, to be colonizated in human body intestinal canal, reproductive system, thereby can produce the active beneficial microorganism general name that definite health efficacy improves host's microecological balance, performance beneficial effect, it has the multiple efficacies such as the lactose intolerance of alleviation, adjustment intestinal microecology, enhancing autoimmunity, at present increasing researcher focuses on probio, recognizes gradually their huge effect.
In probio, be subject to Bifidobacterium and the lactic acid bacteria of extensive concern, after in taking in the humans and animals body, their specific bacterial strain can be settled down on intestinal mucosa, the built-in group of enteron aisle and prevent that harmful microorganism from adhering to thereon, can promote the microorganism formulation of growing of bion health by keeping natural microorganisms fauna in intestines, help to maintain the health of humans and animals.
Bacteroides fragilis (
Bacteroides fragilis) as a kind of Gram-negative, shaft-like, blunt round and dense the dying in two ends, pod membrane is arranged, without brood cell, motorless obligate anaerobes, it is divided into enterotoxin type and the non-product enterotoxin type of producing.Bacteroides fragilis, as the part of people and animal intestinal normal flora, mainly is stored in colon, in addition, but the also field planting growth of respiratory tract, intestines and stomach and urogenital tract mucous membrane.At present, studying more is that bacteroides fragilis is as a kind of conditioned pathogen, when host's mucous membrane is impaired, can invade submucosa, cause infection, also can flow through blood, cause other organ of health such as enteron aisle, abdominal cavity, liver, lung, brain tissue pyogenic infection and the abscess and cause the symptom such as acute and chronic diarrhea of occurring together; In addition, bacteroides fragilis also has facilitation to the generation of colorectal cancer.
Yet bacteroides fragilis is not only a kind of conditioned pathogen.1991, Zhang Jijie has delivered " separation of a kind of nontoxic bacteroides fragilis is identified ", it has been reported about September nineteen eighty-three from a well-developed infant faeces, separating the large and purer bacterium of output, through a series of evaluation, basic test and observation on Clinical Application, this bacterium belongs to a strain in the bacteroides fragilis group without toadstool, be the probio of human body, and name the bacterial strain into BF839.Thus, study and found, bacteroides fragilis is also a kind of probio.But bacteroides fragilis is as a kind of probio, and the related application in the composition of preparation prevention animal intestinal disease, and report is not yet arranged at present.
Summary of the invention
The object of the present invention is to provide the application of bacteroides fragilis in the composition of preparation prevention animal intestinal disease, described bacteroides fragilis depositary institution name is called China Committee for Culture Collection of Microorganisms's common micro-organisms center, the depositary institution address is No. 3, Yard 1, BeiChen xi Road, Chaoyang District, Beijing City, preservation date is on March 12nd, 2013, deposit number is CGMCC No.7280, and Classification And Nomenclature is
Bacteroides fragilis.
In order to address the above problem, the technical solution adopted in the present invention is:
The application of bacteroides fragilis in the composition of preparation prevention animal intestinal disease.
Wherein, the application of bacteroides fragilis in the animal feed additive of preparation prevention animal intestinal disease.
Wherein, described composition is food or pharmaceutical composition.
Wherein, described composition is pill, tablet, granular preparation, capsule, oral liquid or tube feed preparation.
Wherein, described composition is the liquid bacterial suspension that contains described bacteroides fragilis.
Wherein, the content of described bacteroides fragilis in described composition is 10
8~ 10
10Cfu/ml.
The invention has the beneficial effects as follows:
The present invention has excavated the new purposes of bacteroides fragilis, has opened up a new application.The present invention proves by experiment, the bacteroides fragilis safety non-toxic, and pharmacological action is strong, for the animal intestinal disease, good prophylactic treatment effect is arranged, thereby has indicated that bacteroides fragilis has well edible and prospect in medicine.Bacteroides fragilis, as a kind of probio, can be used for preparing the composition of animal intestinal disease, and as animal feed additive, bacteroides fragilis can prevent the animal intestinal disease as animal feed additive, promotes the healthy growth of animal.
The specific embodiment
Below by embodiment, the present invention is described in further details, these embodiment only are used for illustrating the present invention, do not limit the scope of the invention.
The preparation of embodiment 1 bacteroides fragilis CGMCC No.7280 bacterium liquid
(1) in infant faeces, separate bacteroides fragilis CGMCC No.7280
By " normal flora inspection technique ", take 0.5 gram stool, be placed in the test tube that 4.5ml physiological saline first is housed, become 10 with this serial dilution
-1~ 10
-6, by the rare long-pending degree of height, dripped on the Bd culture medium flat plate to low rare long-pending degree, be placed in the anaerobic gas generation box and add the anaerobic gas generation bag and carry out the anaerobism cultivation.Put 37 ℃, can opening inspection after 2 ~ 7 days.Choose single bacterium colony and carry out pure culture, dyeing microscopic examination, cultural character, Physiology and biochemistry detection.
(2) bacterium that increases of bacteroides fragilis CGMCC No.7280 is cultivated and bacterium solution preparation
Choosing single colony inoculation after purifying increases bacterium and cultivates in the tryptone meat soup of improvement, the centrifugation of gained bacterium liquid, rotating speed 3000r/min, centrifugal 15min, remove supernatant, after sediment washs with physiological saline, the sediment normal saline dilution, with the Maxwell opacity tube, do the bacterium number and measure, be diluted to 10
8Cfu/ml, 10
9Cfu/ml, 10
10Cfu/ml, save backup.
Embodiment 2 bacteroides fragilis CGMCC No.7280 virulence experiments
Adopt the bacteroides fragilis CGMCC No.7280 bacterium liquid of embodiment 1 preparation to carry out following experiment:
(1) chmice acute virulence experiment
Get 60 of body weight 22 ± 2 gram C57BR/C mouse (male and female half and half), be divided into high dose group, low dose group and control group, each organizes 20.Every mouse gavage every day 10 of high dose group
12Cfu/ml bacterium liquid 0.5ml, low dose group gavage every day 10
9Cfu/ml bacterium liquid 0.5ml, control group gavage every day 0.5ml physiological saline.Continuous Observation 14 days.
Experimental result: the mouse normal growth, have no dead, LD50 does not measure.
(2) rat virulence experiment
Get 30 of 150 ± 20 gram SD rats (male and female half and half), be divided into 3 groups: high low dose group and control group.Every rat gavage every day 10 of high dose group
12Cfu/ml bacterium liquid 2ml, low dose group gavage every day 10
9Cfu/ml bacterium liquid 2ml, control group gavage every day 2ml physiological saline.Continuous Observation 14 days, phlebotomize after 14 days and survey blood picture, liver kidney merit.Get stomach and intestine liver spleen tissue and do the pathological section electron microscopic observation.
Experimental result: be showed no obvious abnormalities.
(3) rhesus macaque virulence experiment
Get 10 of rhesus macaquies (male and female half and half), be divided into 2 groups: high low dose group and control group.Every of high dose group rhesus macaque every day oral 10
12Cfu/ml bacterium liquid 100ml, low dose group every day oral 10
9Cfu/ml bacterium liquid 100ml.Continuous Observation 60 days.After 14 days, 30 days, 45 days, 60 days, phlebotomize respectively and survey blood picture, liver kidney merit, thought-read electrograph.Get stomach and intestine liver spleen tissue and do the pathological section electron microscopic observation.
Experimental result: be showed no obvious abnormalities.
Embodiment 3 bacteroides fragilis CGMCC No.7280 are for the prevention effect of diarrhoea
(1) mouse is divided into to two groups, administration group and control group, 10 every group.Animal fasting feedwater before modeling, control group is by ampicillin sodium (adding physiological sodium chloride solution prepares) 0.2g gavage subsequently, every 0.5ml Bid, the administration group adds with 10 every day
8The bacterium liquid gavage of cfi/ml, each 0.5ml.After 1 week, observe mouse and diarrhoea whether occurs, get stool in mice and do the flora analysis.
Experimental result: diarrhoea, draining sample or mushy stool all appear in control group mice; The diarrhea rate of administration group mouse is starkly lower than control group.The body weight of administration group mouse is apparently higher than control group.The flora analysis result sees the following form:
| ? | Enterobacteria | Enterococcus | Lactobacillus | Bifidobacterium |
| Control group | 4.68±0.55 | 6.33±0.61 | 8.00±0.32 | 8.17±0.46 |
| The administration group | 9.98±0.48* | 8.58±0.54* | 8.11±0.27 | 8.22±0.44 |
This studies show that, bacteroides fragilis has certain prevention effect for animal diarrhoea, when dosage reaches 10
8During cfi/ml, preventive effect is the most obvious.
Claims (6)
1. the application of bacteroides fragilis in the composition of preparation prevention animal intestinal disease.
2. the application of bacteroides fragilis according to claim 1 in the composition of preparation prevention animal intestinal disease is characterized in that: the application in the animal feed additive of preparation prevention animal intestinal disease.
3. the application of bacteroides fragilis according to claim 1 in the composition of preparation prevention animal intestinal disease, it is characterized in that: described composition is food or pharmaceutical composition.
4. the application of bacteroides fragilis according to claim 3 in the composition in preparation prevention animal intestinal disease, it is characterized in that: described composition is pill, tablet, granular preparation, capsule, oral liquid or tube feed preparation.
5. the application of bacteroides fragilis according to claim 1 in the composition in preparation prevention animal intestinal disease, it is characterized in that: described composition is the liquid bacterial suspension that contains described bacteroides fragilis.
6. the application of bacteroides fragilis according to claim 1 in the composition in preparation prevention animal intestinal disease, it is characterized in that: the content of described bacteroides fragilis in described composition is 10
8~ 10
10Cfu/ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013103599509A CN103404707A (en) | 2013-08-19 | 2013-08-19 | Application of bacteroides fragilis in preparation of compositions for preventing intestinal diseases of animals |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013103599509A CN103404707A (en) | 2013-08-19 | 2013-08-19 | Application of bacteroides fragilis in preparation of compositions for preventing intestinal diseases of animals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103404707A true CN103404707A (en) | 2013-11-27 |
Family
ID=49597797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013103599509A Pending CN103404707A (en) | 2013-08-19 | 2013-08-19 | Application of bacteroides fragilis in preparation of compositions for preventing intestinal diseases of animals |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103404707A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106387314A (en) * | 2015-07-31 | 2017-02-15 | 广州知易生物科技有限公司 | Applications of Bacteroides fragilis in animal breeding |
| CN106399141A (en) * | 2015-07-31 | 2017-02-15 | 广州知易生物科技有限公司 | Bacteroides fragilis and applications thereof |
| CN109481475A (en) * | 2017-09-11 | 2019-03-19 | 广州知易生物科技有限公司 | Application of the bacteroides fragilis in the reinforcing agent of preparation enhancing gut barrier function |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1056314A (en) * | 1990-05-03 | 1991-11-20 | 张李阶 | Useful bacterial strain of one strain and application thereof |
| CN103146620A (en) * | 2013-03-25 | 2013-06-12 | 广州知光生物科技有限公司 | Bacteroides fragilis with characteristics of probiotics |
| CN103156887A (en) * | 2013-03-18 | 2013-06-19 | 广州知光生物科技有限公司 | Application of bacteroides fragilis in preparation of composition for promoting bifidobacterium and lactobacillus to grow |
-
2013
- 2013-08-19 CN CN2013103599509A patent/CN103404707A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1056314A (en) * | 1990-05-03 | 1991-11-20 | 张李阶 | Useful bacterial strain of one strain and application thereof |
| CN103156887A (en) * | 2013-03-18 | 2013-06-19 | 广州知光生物科技有限公司 | Application of bacteroides fragilis in preparation of composition for promoting bifidobacterium and lactobacillus to grow |
| CN103146620A (en) * | 2013-03-25 | 2013-06-12 | 广州知光生物科技有限公司 | Bacteroides fragilis with characteristics of probiotics |
Non-Patent Citations (3)
| Title |
|---|
| 吴彦彬等: "拟杆菌的研究及应用", 《拟杆菌的研究及应用》, no. 1, 26 February 2007 (2007-02-26), pages 66 - 69 * |
| 张季阶等: "脆弱拟杆菌（BF839）菌液的临床应用研究", 《中国生物制品学杂志》, vol. 8, no. 2, 28 February 1995 (1995-02-28), pages 63 - 65 * |
| 肖尔彬等: "BF-839脆弱拟杆菌对肉仔鸡生产性能的影响", 《现代畜牧兽医》, 15 March 2012 (2012-03-15), pages 40 - 42 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106387314A (en) * | 2015-07-31 | 2017-02-15 | 广州知易生物科技有限公司 | Applications of Bacteroides fragilis in animal breeding |
| CN106399141A (en) * | 2015-07-31 | 2017-02-15 | 广州知易生物科技有限公司 | Bacteroides fragilis and applications thereof |
| CN109481475A (en) * | 2017-09-11 | 2019-03-19 | 广州知易生物科技有限公司 | Application of the bacteroides fragilis in the reinforcing agent of preparation enhancing gut barrier function |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108004189A (en) | A kind of compound probiotic lactic acid bacteria powder and preparation method and application | |
| CN103156888A (en) | Application of bacteroides fragilis in preparation of composition for treating inflammatory bowel diseases | |
| CN103146620A (en) | Bacteroides fragilis with characteristics of probiotics | |
| CN103142656A (en) | Application of bacteroides fragilis in preparing composition for preventing and treating colon cancer | |
| JP4623896B2 (en) | Bacterial strains, processed plant extracts and probiotic compositions used in humans and animals | |
| CN104232515B (en) | A kind of animal bifidobacteria and its application | |
| CN102326678B (en) | Penta-composite probiotic powder preparation and preparation method thereof | |
| CN105434476A (en) | Application of bacteroides fragilis to prevention and/or treatment of inflammatory bowel diseases (IBDs) | |
| CN102112140A (en) | Effects of probiotics on humans and animals under environmental or biological changes | |
| CN106754579A (en) | A kind of bacillus coagulans and application thereof | |
| CN104922586B (en) | A kind of preparation and its application of the probiotics fermention Chinese medicine preparation for preventing chicken coccidiasis | |
| CN102697888A (en) | Traditional Chinese medicine fermented preparation for preventing and treating piglet diarrhea and preparation method thereof | |
| CN110521785A (en) | Probiotics fermention functional food and its preparation | |
| CN110205270A (en) | A kind of application of lactobacillus paracasei L9 that alleviating cultivated animals constipation | |
| WO2019227418A1 (en) | Composition and uses thereof | |
| CN118593558B (en) | Animal bifidobacterium and radish seed composition with synergistic effect of preventing and treating functional constipation | |
| US20240390436A1 (en) | Bifidobacterium animalis subsp. lactis atm-209 inhibiting helicobacter pylori and application thereof | |
| CN103082294A (en) | Application of bacteroides fragilis in preparation of composition for treating diarrhea | |
| CN101336938A (en) | Use of probiotics in preparing composition for treating and preventing hand-foot-mouth disease | |
| CN103404707A (en) | Application of bacteroides fragilis in preparation of compositions for preventing intestinal diseases of animals | |
| CN108938789A (en) | A kind of more bacterium combination formulations of the adjusting intestinal microecology containing xylo-oligosaccharide | |
| CN116210836A (en) | Solid beverage composition containing probiotics and application thereof | |
| CN101134051A (en) | Application of clostridium butyricum, condensate bacillus and bifidobacteria in the preparation of medicament for treating irritable bowel syndrome, cold diarrhoea and drink diarrhoea | |
| CN101849969A (en) | Application of butyric acid producing beneficial bacterium in preparing preparation for preventing and treating severe disease gut barrier injury and post-injury complication | |
| CN103156886A (en) | Application of bacteroides fragilis in preparation of composition for treating bacterial vaginitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU ZHIYI BIOLOGICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: GUANGDONG ZHIGUANG BIOLOGICAL TECHNOLOGY CO., LTD. Effective date: 20150424 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 510515 Guangdong province high tech Industrial Development Zone of Guangzhou Science City on Guangzhou Road No. 3 international business incubator F District No. F321 room Applicant after: Guangdong informed Biotechnology Co.,Ltd. Address before: Evelyn Lu Yun Chia Street Baiyun District of Guangzhou City, Guangdong province 510515 No. 3 Room 301 Applicant before: Guangzhou Zhiguang Biotechnology Co.,Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: ZHIGUANG BIOLOGICAL SCI-TECH CO., LTD., GUANGZHOU TO: GUANGDONG ZHIGUANG BIOLOGICAL TECHNOLOGY CO., LTD. Free format text: CORRECT: ADDRESS; FROM: 510515 GUANGZHOU, GUANGDONG PROVINCE TO: 510663 GUANGZHOU, GUANGDONG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150424 Address after: 510663 Guangdong province high tech Industrial Development Zone of Guangzhou Science City on Guangzhou Road No. 3 international business incubator F District No. F322 room Applicant after: GUANGZHOU ZHIYI PHARMACEUTICAL, Inc. Address before: 510515 Guangdong province high tech Industrial Development Zone of Guangzhou Science City on Guangzhou Road No. 3 international business incubator F District No. F321 room Applicant before: Guangdong informed Biotechnology Co.,Ltd. |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20131127 |